Ii-Key-SARS-CoV-2 vaccine progress Ii-Key-H1 Swin
Post# of 36568
(Total Views: 410)
Posted On: 08/04/2020 9:01:04 AM
Ii-Key-SARS-CoV-2 vaccine progress
Ii-Key-H1 Swine flu vaccine opportunity
SEC Filings and plans for listing on a national exchange
MIRAMAR, Fla., Aug. 04, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO) today announced that it will hold an investor conference call on Thursday, August 27th at 9:00 am.
During the call, NGIO CEO Joe Moscato will discuss the company’s efforts to develop a vaccine for the COVID-19 pandemic, and the use of the Ii-Key technology as a platform for developing vaccines for other viruses with pandemic potential, including the G4 EA H1 Swine flu that is currently emerging in China. Mr. Moscato will also update shareholders on the company’s plans and timing for listing NGIO on a national exchange.
Mr. Moscato said, “For over a year, we have focused our attention on realizing the value of the Ii-Key platform technology for the development of immunotherapies for cancer and vaccines for infectious disease by spinning out NGIO as a separate, public company. We have given our Generex shareholders two share dividends for NGIO, rewarding our valued shareholders who have supported our reorganization efforts. With our Form 10 filed, NGIO is now a public company, and we are making significant progress toward realization of our goal to list the company on a national exchange with the signing of one funding instrument and the planned closing of two additional funding vehicles in the near future.”
Mr. Moscato continued, “We are excited about the opportunities that are in front of us with the impending funding and market listing that will enable us to expand the Ii-Key oncology platform with plans to conduct a clinical trial of AE37 in bladder cancer to augment our work in breast and prostate cancers, and the initiation of clinical development work in melanoma with immunotherapeutic Ii-Key peptide vaccines against the tumor antigens GP-100 and TYR (tyrosinase). During the shareholders call, I will provide an update on our progress in developing our Ii-Key-SARS-CoV-2 vaccine including the response from the FDA on our pre-IND briefing package. I will also discuss how the Ii-Key vaccine technology can be established as the preferred platform for developing rapid vaccines against other pandemic threats that continue to emerge globally, focusing on the swine flu outbreak that is currently emerging in China. I look forward to speaking with shareholders on August 26th.”
Dial-in instructions for the investor conference call will be announced prior to the meeting date.
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Cautionary Note Regarding Forward-Looking Statements
Ii-Key-H1 Swine flu vaccine opportunity
SEC Filings and plans for listing on a national exchange
MIRAMAR, Fla., Aug. 04, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO) today announced that it will hold an investor conference call on Thursday, August 27th at 9:00 am.
During the call, NGIO CEO Joe Moscato will discuss the company’s efforts to develop a vaccine for the COVID-19 pandemic, and the use of the Ii-Key technology as a platform for developing vaccines for other viruses with pandemic potential, including the G4 EA H1 Swine flu that is currently emerging in China. Mr. Moscato will also update shareholders on the company’s plans and timing for listing NGIO on a national exchange.
Mr. Moscato said, “For over a year, we have focused our attention on realizing the value of the Ii-Key platform technology for the development of immunotherapies for cancer and vaccines for infectious disease by spinning out NGIO as a separate, public company. We have given our Generex shareholders two share dividends for NGIO, rewarding our valued shareholders who have supported our reorganization efforts. With our Form 10 filed, NGIO is now a public company, and we are making significant progress toward realization of our goal to list the company on a national exchange with the signing of one funding instrument and the planned closing of two additional funding vehicles in the near future.”
Mr. Moscato continued, “We are excited about the opportunities that are in front of us with the impending funding and market listing that will enable us to expand the Ii-Key oncology platform with plans to conduct a clinical trial of AE37 in bladder cancer to augment our work in breast and prostate cancers, and the initiation of clinical development work in melanoma with immunotherapeutic Ii-Key peptide vaccines against the tumor antigens GP-100 and TYR (tyrosinase). During the shareholders call, I will provide an update on our progress in developing our Ii-Key-SARS-CoV-2 vaccine including the response from the FDA on our pre-IND briefing package. I will also discuss how the Ii-Key vaccine technology can be established as the preferred platform for developing rapid vaccines against other pandemic threats that continue to emerge globally, focusing on the swine flu outbreak that is currently emerging in China. I look forward to speaking with shareholders on August 26th.”
Dial-in instructions for the investor conference call will be announced prior to the meeting date.
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Cautionary Note Regarding Forward-Looking Statements
(0)
(0)